Clinical Trial Update: Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection [Phase 2, Phase 3]

View source ↗

Summary

Update on a study of Apricitabine, an NRTI for drug-resistant HIV infection; the Phase 2/Phase 3 trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Apricitabine (Apricitabine)

Snippet

Sponsor: Avexa | Conditions: HIV Infections | Phase 2, Phase 3 | Status: TERMINATED